Loading…
← CockpitCompetitor Analysis › FDMT 4D Molecular Therapeutics, Inc.Open in the cockpit ↗

4D Molecular Therapeutics, Inc.FDMTCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum weak 33
Mkt cap
$578M
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$11.3M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 18.7%
Hurdle
n/a
no reverse DCF
Next earnings
100 days
26 Feb 2027
Close · USD$10.46
1D-3.1%
1W-19.5%
1M-20.1%
3M-35.0%
6M+23.5%
YTD+39.5%
1Y-4.5%
ATR %9.0%
Beta1.90
52w lowhigh38.2% off high

What 4D Molecular Therapeutics does

Employees: 196

4D Molecular Therapeutics at a glance

Size 4D Molecular Therapeutics (FDMT) is a United States Health Care company (Biotechnology) with a market value of $578M, the 2568th largest of 3,085 United States companies the cockpit tracks. Shares closed at $10.46 on 18 Nov 2026.

Performance Over six months the shares gained 23.5%, against -20.4% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 19 in its peer set.

Growth Revenue grew 79,952.5% over the last twelve months (peer median +9.1%); the operating margin is -226.1% (peer median -49.9%).

Valuation It trades at 3.2× enterprise value to sales against a peer median of 3.9× (7th cheapest of 16).

Short interest Short interest is 19.7% of the free float (30 Oct 2026).

Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026FDMT 120Peer median 79
Six months, rebased to 100: 4D Molecular Therapeutics against the median of its 20 peers (local-currency closes).

4D Molecular Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$96.1M$85.2M$37,000$20.7M$3.13M
Revenue growth—+230,195%-100%+562%—
Gross profit$87.9M$77.6M-$6.67M$15.0M-$751,000
EBITDA-$209M-$152M-$181M-$107M-$106M
Net income-$200M-$140M-$161M-$101M-$107M
Free cash flow-$166M-$110M-$138M-$78.6M-$98.2M
Capital expenditure$34,000$536,000$3.79M$2.77M$11.5M
Total debt$38.4M$21.4M$24.6M$14.7M$16.1M

Quarterly statements and history in the cockpit →

4D Molecular Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-50%0%+50%+100%1672GNFT300404SANA300871688639SRZNDSGN1521603387JANXGERN688197FDMT6-month return →1-month return →
Up and to the right = strong over both horizons. 4D Molecular Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+20,000%+40,000%+60,000%+80,000%0×1,000×1672GNFT9637FDMTRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. 4D Molecular Therapeutics is the large dot.

4D Molecular Therapeutics competitors and peer comparison

How 4D Molecular Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

4D Molecular Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureFDMTPeer medianRank in peer set
1-month return-20.1%-12.2%5th lowest of 21
6-month return+23.5%-20.4%2nd highest of 19
Distance from 52-week high-38.2%-49.8%6th highest of 21
Revenue growth (TTM)+79,952.5%+9.1%highest of 17
Operating margin-226.1%-49.9%6th lowest of 17
EV / Sales3.2×3.9×7th cheapest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
4D Molecular Therapeutics FDMTUnited States$578M+23%+79,952%-226%3.2×n/an/a
Ascletis Pharma 1672.HKHong Kong$571M-72%-59%-71,976%1,794.8×n/an/a
Genfit GNFT.PAFrance$571M+22%+28%-130%11.0×39.8%+143.5%
Alebund Pharmaceuticals (Jiangsu) 9637.HKHong Kong$595Mn/a+674%-495%26.8×n/an/a
Boji Medical Technology 300404.SZChina$561M-6%+32%4%3.4×31.9%+27.2%
Sana Biotechnology SANAUnited States$554M-41%n/an/an/an/an/a
Hvsen Biotechnology 300871.SZChina$553M-22%+2%17%2.3×n/an/a
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%1.9×n/an/a
Surrozen SRZNUnited States$605M+17%+192%-485%48.5×n/an/a
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
Wave Life Sciences WVEUnited States$546M-55%-35%-321%2.2×n/an/a
Climb Bio CLYMUnited States$546M-12%n/an/an/an/an/a
Frontage 1521.HKHong Kong$542M+113%+10%8%2.3×14.3%+15.4%
Getein Biotech 603387.SSChina$625M-13%+8%21%2.6×-8.9%-1.3%
Janux Therapeutics JANXUnited States$631M-28%+133%-599%n/an/an/a
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%4.4×n/an/a
Geron GERNUnited States$638M-21%+19%-8%2.8×n/an/a
Beijing Bohui Innovation Biotechnology 300318.SZChina$518M-20%-1%-13%6.2×n/an/a
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%38.1×n/an/a
LongBio Pharma (Suzhou) 1779.HKHong Kong$510Mn/an/an/an/an/an/a
Valneva VLA.PAFrance$508M-6%-27%-87%3.9×n/an/a

Questions

Which companies are 4D Molecular Therapeutics's closest peers?
The cockpit's peer set: Ascletis Pharma (1672.HK), Genfit (GNFT.PA), Alebund Pharmaceuticals (Jiangsu) (9637.HK), Boji Medical Technology (300404.SZ), Sana Biotechnology (SANA), Hvsen Biotechnology (300871.SZ), Anhui Huaheng Biotechnology (688639.SS), Surrozen (SRZN).
Is 4D Molecular Therapeutics expensive compared with its peers?
On ev / sales it trades at 3.2× against a peer median of 3.9×, 7th cheapest of 16 in its peer set.
How has 4D Molecular Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +23.5% against -20.4% for the median peer; over one year -4.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.